Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by westcoast1000on Jun 08, 2023 3:37pm
275 Views
Post# 35487125

Other kinds of prevarication and misdirection

Other kinds of prevarication and misdirectionOn the Stocktwits board, various posters are saying Matt Coffey has no incentive to sell  the company because he does not own shares, and does not care about dilution because he would gat a royalty on future sales. Both statements are wrong.

A few months back, Proboscises provided a valuable summary of the options held all the significant members of management. IIRC, Matt has about 1.8 million options. Evenyone else has plenty of options also. At a sale of only $2 billion for the company, or about $30 per share, Matt has options a low prices that would be worth $54 million US before taxes. After taxes, that is roughly $60 million Cdn.

Beyond that, the royalty granted to the founders has been ended because every founder but Matt is gone, and I think the options replaced the royalty (I could be wrong about that part).

In sum, they have strong incentives to sell the company.

Finally, here is corporate governance 101: Matt would not be the one to decide to sell. That is the responsibility of the board, who we hire and pay for to protect the interests of shareholders in a public company. Strategic decisions, including sale or partnership of the company, is made by the BOD. 
<< Previous
Bullboard Posts
Next >>